Navigation Links
Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
Date:8/17/2011

TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA™ (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts.

The presentations are:

  • "Analysis of 2,457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF Trap-Eye and Ranibizumab in Neovascular AMD" will be presented by Jeffrey S. Heier, M.D. on Sunday, August 21 at 8:21 a.m.  

  • "One-year Results of the DA VINCI Study of VEGF Trap-Eye in DME" will be presented by Diana V. Do, M.D. on Sunday, August 21 at 2:48 p.m.  

  • "The 6-Month (Primary Endpoint) Results of the Phase 3 GALILEO Study: VEGF Trap-Eye in CRVO" will be presented by Jean-Francois Korobelnik, M.D. on Monday, August 22 at 8:20 a.m.  

  • "Trap-Eye in CRVO: 1-year Results of the Phase 3 COPERNICUS Study" will be presented by W. Lloyd Clark, M.D. on Monday, August 22 at 8:28 a.m.  

  • About EYLEA™ (aflibercept injection)Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body.  Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs.  However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.  

    EYLEA, also known as VEGF Trap-Eye, is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  EYLEA is a specific and hi
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
    2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
    5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
    6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
    8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
    9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
    10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
    11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
    (Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
    (Date:9/22/2014)... , September 22, 2014 ... Line Development Market by Product (Equipment, Media and Reagents), ... Engineering & Regenerative medicine, Toxicity Testing, Research, Drug ... published by MarketsandMarkets, analyzes and studies the major ... Browse 114 market data tables and 64 ...
    Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
    ... PARSIPPANY, N.J., Jan. 31, 2011 PDI, Inc. (Nasdaq: ... officer, is scheduled to present at the UBS 21st Annual Global ... at the Grand Hyatt New York. The live ... company,s website at http://www.pdi-inc.com . The webcast will be archived ...
    ... Calif., Jan. 31, 2011 OXIS International, Inc., (OTC ... today announced highly favorable final results from an initial ... patent-pending ERGOFLEX™ joint health formula, launched commercially ... of pain was statistically significant after as little as ...
    Cached Medicine Technology:Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
    (Date:9/22/2014)... By Amy Norton ... -- Tiny preemies may fare better when newborn intensive care ... time with their infants, a new study finds. Researchers ... were more alert and were less distressed when their NICU ... families. The findings, published online Sept. 22 in the ...
    (Date:9/22/2014)... transplant seems futuristic, if not impossible. But with ... Defense, researchers at University of California, San Diego ... of an entire, functional eye a reality. , ... grail for vision restoration," said Jeffrey Goldberg, MD, ... colleagues at University of Pittsburg Medical Center and ...
    (Date:9/22/2014)... 22, 2014 An inventor and anesthesiologist ... the problem of side-sleeping. "My lower arm always became ... designed a solution to this problem," she said. "It’s ... to have your arm 'fall asleep.'" , The Sleeping ... her side more comfortably. It avoids pain and restlessness ...
    (Date:9/22/2014)... 22, 2014. Kessler researchers have published a pilot ... wellness program in people with multiple sclerosis (MS). ... health, perceived stress, and pain. "Development and ... living with MS: Description and outcomes" was epublished ... International Journal of MS Care (doi: ...
    (Date:9/22/2014)... News) -- Scans of young children,s brains might ... finding could potentially allow doctors to identify those ... preliminary research suggests. "Early identification and interventions ... well as most neurodevelopmental disorders," the study,s senior ... child and adolescent psychiatry at University of California, ...
    Breaking Medicine News(10 mins):Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
    ... authored by two Memorial University faculty members published in ... the Public Library// of// Science (PLoS). Drs. Amin A. ... the paper, entitled, "Prevalence of depression among house holds ... the mental health policy." ,Dr. Muhammad Gadit ...
    ... allow a pioneering doctor, currently under house arrest in Henan ... award for her work on behalf// of HIV/AIDS patients, it ... had permission to travel," retired professor Gao Yaojie, 79, told ... holding her under house arrest for two weeks. ...
    ... found supporting evidence to implicate insulin-like growth factor receptor ... ,In a previous research, Terry J. Smith, M.D. and ... immunoglobulins and IGF-1R as a cause of inflammation and ... , The discovery of these mechanisms in ...
    ... University have developed a novel spraying method for delivering ... a new low-cost and scaleable technique that offers needle-free ... methods. The process could one day provide a better ... related spread of HIV/AIDS in the developing world. ...
    ... If you are cooking with garlic, crush the pods first ... benefits and medicinal properties are well known. It has long ... folklore for preventing everything from the common cold and flu ... herbal medicine and it contains compounds shown to help prevent ...
    ... on Friday plan to distribute 250,000 city-branded condoms as ... the spread of HIV// and other sexually transmitted infections, ... purple and yellow package is printed in English and ... Coming together to stop HIV in D.C.' The first ...
    Cached Medicine News:Health News:A Single Biological Mechanism Behind Several Autoimmune Disorders 2Health News:Scientists Partner to Develop and Distribute New Tuberculosis Vaccine 2Health News:Free Condoms Distribution to Prevent HIV in Washington 2
    ... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
    ... Temporary, Transvenous Pacing Lead System Features an ... lubricated guide catheter. The system is designed ... The system is disposable, for temporary single ... of 7 days or less. The lead ...
    ... system provides an ideal solution for ... laboratory, satellite lab and the clinic ... method with wedge-smear technology, the ADVIA ... in a safe enclosed environment. The ...
    It is a cardio-pulmonary exercise testing device....
    Medicine Products: